- Oral presentation
- Open Access
O214. Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
© Yirrell et al; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Viral Load
- Virological Suppression
- Virological Finding
- Boost Protease Inhibitor
The SARA trial recently demonstrated a non-inferior CD4 response, over median follow-up of 60 weeks, with a boosted protease inhibitor monotherapy (bPImono) maintenance second-line regimen compared with continuous combination therapy (CT), suggesting this approach could maintain effectiveness whilst improving tolerability and decreasing costs [International AIDS Conference 2010, LBPE16]. Analysis of virological response and genotypic drug resistance is reported here.
Eligible participants in the DART trial who received 24 weeks of lopinavir/ritonavir-containing second-line CT were randomised to maintain current CT or to reduce to bPImono within a nested pilot trial (SARA). No real-time virology was performed, but stored plasma samples from time at switch to second-line, randomisation after 24 weeks of second-line, and 24 weeks after randomisation were assayed for HIV-1 RNA viral load (VL) by Roche Amplicor v1.5. Genotypic resistance was assessed on samples with VL >1000 c/ml at this latest time point, along with paired samples at switch to second-line. All analyses are intention-to-treat.
192 participants were randomised to CT (n=95) or bPImono (n=97). 77% (135/173) had VL<50 c/ml at randomisation. 44 (23%) participants were taking bPI with NRTI only, 29 (15%) with NNRTI only, and 119 (62%) with both. Virological suppression at week 24 was higher (trend test p=0.007) for participants on CT vs bPImono: 77% (70/91) vs 60% (56/94) had VL <50 c/ml, 90% (82) vs 74% (72) had VL <200 c/ml, and 94% (86) vs 84% (81) had VL <1000 c/ml. Restricting to patients with VL <50 c/ml at randomisation, 85% (57/67) vs 66% (43/65) had VL <50 c/ml at week 24. Of the 18 participants with VL >1000 c/ml at week 24, 12 (2 CT, 10 bPImono) have been assessed genotypically. IAS major PI mutations at week 24, not present at switch to second-line, were detected in 2 bPImono participants only. One participant (VL=3600 c/ml) had I54V only, the other (VL=1490 c/ml) M46IM+V82AV. Both isolates were considered fully susceptible to darunavir.
In this study based on retrospective virological testing, bPImono following 24 week second-line induction was associated with an increase in low level viraemia, although generally in the absence of PI resistance. Longer-term trials are required before definitive conclusions can be drawn about the effectiveness of PI monotherapy in populations without access to virological monitoring.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.